CM24 combination improves clinical outcomes in advanced metastatic PDAC in phase II study interim data

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Purple Biotech Ltd. announced positive interim data from its randomized, controlled, open label, multicenter phase II study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma presented at a late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting.   

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents


“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon. 
FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.